4//SEC Filing
Megna Michael R 4
Accession 0001464583-25-000005
CIK 0001730430other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 5:06 PM ET
Size
25.6 KB
Accession
0001464583-25-000005
Insider Transaction Report
Form 4
Megna Michael R
CHIEF ACCOUNTING OFFICER
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-10-20$15.50/sh+791$12,261→ 38,892 total - Exercise/Conversion
Class A Ordinary Share
2025-10-20$10.76/sh+12,787$137,588→ 77,536 total - Exercise/Conversion
Share Option
2025-10-20−9,831→ 0 totalExercise: $11.97Exp: 2032-08-31→ Class A Ordinary Share (9,831 underlying) - Exercise/Conversion
Class A Ordinary Share
2025-10-20$12.97/sh+6,195$80,349→ 45,087 total - Exercise/Conversion
Class A Ordinary Share
2025-10-20$11.97/sh+9,831$117,677→ 64,749 total - Exercise/Conversion
Share Option
2025-10-20−791→ 0 totalExercise: $15.50Exp: 2030-09-09→ Class A Ordinary Share (791 underlying) - Exercise/Conversion
Share Option
2025-10-20−9,831→ 0 totalExercise: $11.10Exp: 2032-04-06→ Class A Ordinary Share (9,831 underlying) - Exercise/Conversion
Share Option
2025-10-20−12,787→ 0 totalExercise: $10.76Exp: 2033-03-31→ Class A Ordinary Share (12,787 underlying) - Sale
Class A Ordinary Share
2025-10-20$38.72/sh−37,255$1,442,514→ 40,281 total - Exercise/Conversion
Class A Ordinary Share
2025-10-20$11.10/sh+9,831$109,124→ 54,918 total - Exercise/Conversion
Share Option
2025-10-20−6,195→ 0 totalExercise: $12.97Exp: 2031-09-01→ Class A Ordinary Share (6,195 underlying) - Sale
Class A Ordinary Share
2025-10-20$39.31/sh−13,235$520,268→ 27,046 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.145 and $39.57. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F4]The option is fully vested and exercisable.
Documents
Issuer
Kiniksa Pharmaceuticals International, plc
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001464583
Filing Metadata
- Form type
- 4
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 5:06 PM ET
- Size
- 25.6 KB